Peredo-Harvey Inti, Rahbar Afsar, Söderberg-Nauclér Cecilia
Department of Neurosurgery, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Department of Medicine, Solna, BioClinicum, Karolinska Institutet, 171 64 Stockholm, Sweden.
Cancers (Basel). 2021 Oct 9;13(20):5051. doi: 10.3390/cancers13205051.
Glioblastoma is a malignant brain tumor with a dismal prognosis. The standard treatment has not changed in the past 15 years as clinical trials of new treatment protocols have failed. A high prevalence of the human cytomegalovirus (HCMV) in glioblastomas was first reported in 2002. The virus was found only in the tumor and not in the surrounding healthy brain tissue. Many groups have confirmed the presence of the HCMV in glioblastomas, but others could not. To resolve this discrepancy, we systematically reviewed 645 articles identified in different databases. Of these, 81 studies included results from 247 analyses of 9444 clinical samples (7024 tumor samples and 2420 blood samples) by different techniques, and 81 articles included 191 studies that identified the HCMV in 2529 tumor samples (36% of all tumor samples). HCMV proteins were often detected, whereas HCMV nucleic acids were not reliably detected by PCR methods. Optimized immunohistochemical techniques identified the virus in 1391 (84,2%) of 1653 samples. These data suggest that the HCMV is highly prevalent in glioblastomas and that optimized immunohistochemistry techniques are required to detect it.
胶质母细胞瘤是一种预后极差的恶性脑肿瘤。在过去15年里，由于新治疗方案的临床试验失败，标准治疗方法一直没有改变。2002年首次报道了胶质母细胞瘤中人类巨细胞病毒（HCMV）的高流行率。该病毒仅在肿瘤中发现，而在周围健康脑组织中未发现。许多研究小组证实了胶质母细胞瘤中存在HCMV，但其他小组未能证实。为了解决这一差异，我们系统地回顾了在不同数据库中检索到的645篇文章。其中，81项研究纳入了采用不同技术对9444份临床样本（7024份肿瘤样本和2420份血液样本）进行的247次分析结果，81篇文章纳入了191项研究，这些研究在2529份肿瘤样本（占所有肿瘤样本的36%）中鉴定出了HCMV。经常检测到HCMV蛋白，而通过PCR方法未能可靠检测到HCMV核酸。优化后的免疫组织化学技术在1653份样本中的1391份（84.2%）中鉴定出了该病毒。这些数据表明，HCMV在胶质母细胞瘤中高度流行，并且需要采用优化后的免疫组织化学技术来检测它。
